3.
Ashworth A: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors
for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:
3785-3790, 2008.
4.
Herceg Z and Wang ZQ: Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair,
genomic integrity and cell death. Mutat Res 477: 97-110, 2001.
5.
Wiltshire TD, Lovejoy CA, Wang T, et al. Sensitivity to poly(ADP-ribose) polymerase (PARP)
inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-
strand break repair. J Biol Chem 285: 14565-14571, 2010.
6.
Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with
inhibitors of poly(ADPribose) polymerase. Nature 434: 913-917, 2005.
7.
Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature 434: 917-921, 2005.
8.
Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from
BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
9.
Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept
trial. Lancet 376: 235-244, 2010
10.
et al
2015 Jan 20;33(3):244-50.
doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.
11.
et al
2014 Jul;7(7):698-707.
12. Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate
Cancer. New Engl J Med 2015 ;373(18) :1697-708.
13.
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable
responses in BRCA carrier ovarian cancer correlating with platinum- free interval. J Clin Oncol
2010; 28: 2512-9.
14.
Ceccaldi R, O’Connor KW, Mouw KW, et al. A unique subset of epithelial ovarian cancers
with platinum sensitivity and PARP inhibitor resistance.
